Clinical Trials Logo

Congestive Heart Failure clinical trials

View clinical trials related to Congestive Heart Failure.

Filter by:

NCT ID: NCT00329485 Terminated - Clinical trials for Congestive Heart Failure

The Effect of Ribose on B-Type Natriuretic Peptide (BNP) Levels in Congestive Heart Failure Patients

Start date: June 2006
Phase: N/A
Study type: Interventional

The purpose of this research study is to test the effectiveness of CORvalen, a medical food, to increase cellular energy sufficiently to change or modify BNP levels in congestive heart failure patients.

NCT ID: NCT00083772 Terminated - Heart Failure Clinical Trials

Use of Nesiritide in the Management of Acute Diastolic Heart Failure

Start date: May 17, 2004
Phase: Phase 4
Study type: Interventional

Primary objective is to assess the effect of nesiritide in decreasing left ventricular (LV) filling pressure, defined as pulmonary artery capillary wedge pressure (PCWP) in a group of patients admitted with acute diastolic heart failure. Secondary objectives include: improvement in symptoms, exercise tolerance, improvement in Doppler diastolic filling parameters in patients with diastolic heart failure.

NCT ID: NCT00032643 Terminated - Clinical trials for Congestive Heart Failure

A Thyroid Hormone Analog to Fight Heart Failure: Phase II Trial (DITPA)

Start date: June 2004
Phase: Phase 2
Study type: Interventional

Congestive heart failure (CHF) affects 4-5 million Americans, and its prevalence is predicted to increase over the next few decades. Thyroid hormone has unique actions which make it a novel and potentially useful agent for treatment of CHF. Due to possible adverse affects of thyroid hormone, there is interest in developing analogs with fewer undesirable side effects. 3,5- diiodothyropropionic acid (DITPA) has been shown to improve diastolic function in both animal models and a recently completed double-blind placebo controlled trial in 19 humans. The goal of the proposed Phase II study is to show safety and demonstrate a medication of efficacy of DITPA needed in patients with CHF. This study is a prerequisite for a larger Phase III trial which would determine whether mortality is improved with DITPA. To better define the appropriate doses, prior to the Phase II study we will conduct an initial pharmacokinetic study.